Viewing data from: Latest 2026-07-01 2026-06-01 2026-05-01 2026-04-01 2026-03-28 2026-02-17 2026-02-10 2025-12-14 2025-02-26 2025-01-25 2024-11-08 2023-07-23 2023-06-15 2023-05-13 2023-01-26 2022-11-22 2022-10-28 2022-09-29 2022-07-09 2022-06-29 2022-04-08 2022-03-09 2021-12-28 2021-05-05 2021-03-12 2020-12-22 2020-11-12 2019-12-14 2019-09-15
NALOXONE HYDROCHLORIDE | N212045 | HIKMA PHARMACEUTICALS USA INC
2 strengths 7 unique patents 0 unique exclusivities
Patents SEC Intel Revenue PTAB Reexams Litigation Petitions Trials Price Trends Medicare D DMF Approvals Label Products
Products (2) Sort: Name ↑ Applicant Strength Approval
Patents (7) Patent # Expiration PED Drug Substance Drug Product Use Code Delist 10722510 Aug 26, 2034 — — Yes U-3110 USE OF NALOXONE FOR THE EMERGENCY TREATMENT OF KNOWN OR SUSPECTED OPIOID OVERDOSE, AS MANIFESTED BY RESPIRATORY AND/OR CENTRAL NERVOUS SYSTEM DEPRESSION, FOR ADULT AND PEDIATRIC PATIENTS — 10973814 Aug 26, 2034 — — Yes U-3110 USE OF NALOXONE FOR THE EMERGENCY TREATMENT OF KNOWN OR SUSPECTED OPIOID OVERDOSE, AS MANIFESTED BY RESPIRATORY AND/OR CENTRAL NERVOUS SYSTEM DEPRESSION, FOR ADULT AND PEDIATRIC PATIENTS — 11135155 Aug 26, 2034 — — Yes — — 11617713 Aug 26, 2034 — — Yes U-3110 USE OF NALOXONE FOR THE EMERGENCY TREATMENT OF KNOWN OR SUSPECTED OPIOID OVERDOSE, AS MANIFESTED BY RESPIRATORY AND/OR CENTRAL NERVOUS SYSTEM DEPRESSION, FOR ADULT AND PEDIATRIC PATIENTS — 11628139 Aug 26, 2034 — — Yes U-3110 USE OF NALOXONE FOR THE EMERGENCY TREATMENT OF KNOWN OR SUSPECTED OPIOID OVERDOSE, AS MANIFESTED BY RESPIRATORY AND/OR CENTRAL NERVOUS SYSTEM DEPRESSION, FOR ADULT AND PEDIATRIC PATIENTS — 11975096 Aug 26, 2034 — — Yes — — 12414915 Aug 26, 2034 — — Yes — —